News | August 13, 2010

First Patient Treated with Thoracic Stent Graft in Aortic Dissection Trial

The first patient has been enrolled in the Medtronic Dissection Trial, which evaluates the clinical performance of the Valiant Thoracic Stent Graft with the Captivia Delivery System for the treatment of acute, complicated Type B aortic dissection, a serious cardiovascular condition associated with high morbidity and mortality.

Medtronic, Inc., in order to expand the use of minimally invasive endovascular procedures, initiated its Dissection Trial in May 2010 and will enroll a total of 50 patients across 25 centers in the United States. The study is being conducted under an Investigational Device Exemption (IDE) in the United States.

Dr. Zvonimir Krajcer, M.D., co-director of the Peripheral Vascular Disease Service at St. Luke’s Episcopal Hospital in Houston, treated the trial’s first patient with Type B aortic dissection.

“Patients with acute, complicated Type B aortic dissection require immediate treatment, and the Valiant Captivia system holds great promise as a minimally invasive treatment for this challenging patient group,” said Dr. Krajcer. “This trial will help to determine if the Valiant Captivia system is a safe and effective alternative to invasive surgery for these patients.”

Aortic dissections are classified as Type A or Type B depending on where they occur. Type A aortic dissections begin in the ascending aorta, the segment closest to the heart, and require surgery to repair. Type B aortic dissections begin in the descending aorta, may extend into the abdomen and, if uncomplicated by rupture or malperfusion, can be treated with medication as a first-line intervention.

Patients with acute, complicated Type B aortic dissections are reported to have a greater than 50 percent likelihood of dying from this disease and as such often require emergent treatment.

Type B aortic dissections have historically been treated with medication or through invasive surgical techniques.

Endovascular stent grafting is an effective way to treat some aortic conditions, such as aneurysms (a bulge in the wall of the aorta). Once deployed, the grafts conform to the wall of the aorta, the body’s main artery, creating a new path for blood flow.

The Valiant Thoracic Stent Graft received the CE Mark in 2005. Indicated for the treatment of a variety of thoracic aortic lesions, the device has been used to treat more than 15,000 patients worldwide.

Both the Valiant Thoracic Stent Graft and the Captivia Delivery System are investigational in the United States, where their use is limited to clinical trials approved by the U.S. Food and Drug Administration.
Medtronic is committed to advancing the treatment of cardiovascular disease through collaboration with leading clinicians, researchers and scientists worldwide.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init